CVS Health which runs the largest US pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug, Yeztugo, to its commercial or ACA plans for now, citing clinical, financial, and regulatory reasons. The drug, a twice-yearly injection priced over $28,000 annually, is not yet included in current US HIV prevention recommendations, Reuters reported.

Advocates call the decision a missed opportunity in fighting the epidemic, which affects 1.3m Americans annually. Gilead remains in talks with insurers and expects broad coverage by mid-2026. Yeztugo has already been added to government programs and state Medicaid plans, and trials show it is nearly 100 percent  effective in preventing HIV.